Eli Lilly announced that two more Phase 3 trials of its experimental obesity drug, retatrutide, showed positive results. The company plans to submit an application to the U.S. Food and Drug Administration in the first quarter of next year.
Drug Details
Retatrutide is designed to target three different metabolic hormones: GLP-1, GIP, and glucagon. In an 80-week trial of adults with severe obesity and established heart disease, the highest weekly dose of retatrutide resulted in an average weight loss of 22.6%.
A different 80-week trial of overweight or obese patients with type 2 diabetes showed that participants given the highest dose lost 20.8% of their body weight and lowered A1C levels by 1.6%. The most common side effects in both trials were nausea and diarrhea.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
